Emergent Biosolutions, Inc. (NYSE:EBS) Chairman Fuad El-Hibri sold 25,000 shares of the stock in a transaction on Thursday, September 14th. The stock was sold at an average price of $38.50, for a total value of $962,500.00. Following the completion of the transaction, the chairman now owns 1,603,763 shares in the company, valued at $61,744,875.50. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Fuad El-Hibri also recently made the following trade(s):

  • On Thursday, September 7th, Fuad El-Hibri sold 16,439 shares of Emergent Biosolutions stock. The stock was sold at an average price of $37.50, for a total value of $616,462.50.
  • On Tuesday, September 5th, Fuad El-Hibri sold 3,100 shares of Emergent Biosolutions stock. The stock was sold at an average price of $37.50, for a total value of $116,250.00.
  • On Thursday, August 31st, Fuad El-Hibri sold 5,461 shares of Emergent Biosolutions stock. The stock was sold at an average price of $37.50, for a total value of $204,787.50.
  • On Thursday, July 27th, Fuad El-Hibri sold 25,000 shares of Emergent Biosolutions stock. The stock was sold at an average price of $36.50, for a total value of $912,500.00.
  • On Thursday, July 20th, Fuad El-Hibri sold 25,000 shares of Emergent Biosolutions stock. The shares were sold at an average price of $35.50, for a total value of $887,500.00.

Emergent Biosolutions, Inc. (NYSE EBS) traded down 0.13% during midday trading on Friday, hitting $38.06. The stock had a trading volume of 385,441 shares. Emergent Biosolutions, Inc. has a 52 week low of $24.47 and a 52 week high of $38.74. The firm has a 50 day moving average of $36.14 and a 200 day moving average of $32.54. The firm has a market cap of $1.57 billion, a price-to-earnings ratio of 24.24 and a beta of 1.23.

Emergent Biosolutions (NYSE:EBS) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $0.13 earnings per share for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.13). Emergent Biosolutions had a net margin of 13.42% and a return on equity of 14.50%. The firm had revenue of $100.77 million during the quarter, compared to the consensus estimate of $111.57 million. During the same period in the prior year, the company posted ($0.05) EPS. The firm’s revenue was up 10.4% compared to the same quarter last year. Equities research analysts predict that Emergent Biosolutions, Inc. will post $1.54 EPS for the current year.

WARNING: “Emergent Biosolutions, Inc. (EBS) Chairman Fuad El-Hibri Sells 25,000 Shares” was published by Daily Political and is owned by of Daily Political. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/09/15/emergent-biosolutions-inc-ebs-chairman-fuad-el-hibri-sells-25000-shares.html.

Several equities analysts have weighed in on the company. BidaskClub upgraded Emergent Biosolutions from a “hold” rating to a “buy” rating in a research note on Friday, August 25th. Zacks Investment Research cut Emergent Biosolutions from a “hold” rating to a “sell” rating in a research note on Monday, July 17th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $44.00.

A number of institutional investors and hedge funds have recently modified their holdings of EBS. Louisiana State Employees Retirement System increased its position in Emergent Biosolutions by 2.2% in the first quarter. Louisiana State Employees Retirement System now owns 14,100 shares of the biopharmaceutical company’s stock worth $409,000 after buying an additional 300 shares in the last quarter. State of Alaska Department of Revenue increased its position in Emergent Biosolutions by 2.7% in the first quarter. State of Alaska Department of Revenue now owns 3,820 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 100 shares in the last quarter. Great West Life Assurance Co. Can increased its position in Emergent Biosolutions by 5.9% in the first quarter. Great West Life Assurance Co. Can now owns 47,682 shares of the biopharmaceutical company’s stock worth $1,384,000 after buying an additional 2,649 shares in the last quarter. State Board of Administration of Florida Retirement System increased its position in Emergent Biosolutions by 213.3% in the first quarter. State Board of Administration of Florida Retirement System now owns 67,106 shares of the biopharmaceutical company’s stock worth $1,949,000 after buying an additional 45,688 shares in the last quarter. Finally, US Bancorp DE increased its position in Emergent Biosolutions by 12.0% in the first quarter. US Bancorp DE now owns 40,985 shares of the biopharmaceutical company’s stock worth $1,191,000 after buying an additional 4,398 shares in the last quarter. Institutional investors and hedge funds own 85.44% of the company’s stock.

About Emergent Biosolutions

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Insider Buying and Selling by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.